The medical community is slow to adopt advanced preventative tools like genomic sequencing. Change will not come from the top down. Instead, educated and savvy patients demanding these tests from their doctors will be the primary drivers of the necessary revolution in personalized healthcare.

For very high-risk premenopausal patients (e.g., 4+ positive nodes), clinicians may recommend continuing ovarian function suppression beyond the standard 5 years, sometimes advocating for permanent oophorectomy. This is based on clinical experience and data suggesting a more durable blunting of recurrence risk with permanent ovarian ablation.

Citing powerful long-term data from the SOFT and TEXT trials, some oncologists are leaning away from chemotherapy for premenopausal patients with intermediate Oncotype scores (e.g., <25). They argue that the substantial, proven benefits of ovarian function suppression (OFS) may be equivalent to the chemotherapy benefit seen in trials like TAILORx.

To improve clinical trial enrollment and patient preparedness, clinicians should "plant the seed" about potential adjuvant therapies early. Discussing options for residual disease during the neoadjuvant phase, rather than after surgery, helps patients plan and avoids overwhelming them with new information at a critical juncture.

Even patients with "low-risk" advanced ovarian cancer face an 85% chance of recurrence. This high baseline risk justifies aggressive upfront combination therapies, like adding bevacizumab, to maximize the potential for a curative outcome without leaving any options off the table.

Oncologists observe that newly diagnosed pancreatic cancer patients now frequently ask about clinical trials. This indicates a significant shift in patient education and empowerment, with individuals actively seeking the most novel treatments available from day one.

Proactive measures like cascade testing and risk-reducing surgeries are lowering new diagnoses. However, improved treatments mean patients are living longer, leading to a larger population of individuals actively managing the disease.

Unlike cancers where testing is selective, it's a universal standard for ovarian cancer. This impacts not only family members through cascade testing but also directly informs the patient's treatment plan, particularly with PARP inhibitors.

When surgeons offer genetic testing at the point of care ("mainstreaming"), uptake is significantly higher than when patients are referred to separate genetic counselors. This model overcomes patient inertia and logistical barriers, and has been shown to improve testing rates across all socioeconomic strata.